Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/435
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHughes, B. G. M.en
dc.contributor.authorBegbie, S.en
dc.contributor.authorMuljadi, N.en
dc.contributor.authorDavidson, A.en
dc.contributor.authorChan, M. M. K.en
dc.contributor.authorCrombie, C.en
dc.contributor.authorBriscoe, K.en
dc.contributor.authorBroad, A.en
dc.contributor.authorMillward, M.en
dc.contributor.authorCoskinas, X.en
dc.contributor.authorLong, J.en
dc.contributor.authorBoyce, A.en
dc.contributor.authorBoyer, M.en
dc.contributor.authorVarma, S.en
dc.contributor.authorChinchen, S.en
dc.contributor.authorPavlakis, N.en
dc.contributor.authorVeillard, A. S.en
dc.contributor.authorTognela, A.en
dc.contributor.authorStockler, M. R.en
dc.contributor.authorLewis, C. R.en
dc.contributor.authorEspinoza, D.en
dc.contributor.authorAbdi, E.en
dc.date.accessioned2018-06-16T20:33:54Z-
dc.date.available2018-06-16T20:33:54Z-
dc.date.issued2015en
dc.identifier.citation26, (11), 2015, p. 2280-2286en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/435-
dc.description.abstractBackground: We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. Patients and methods: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. Results: Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. Conclusion: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further.<br />en
dc.languageenen
dc.relation.ispartofAnnals of Oncologyen
dc.titleA phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: The Australasian lung cancer trials group NITRO trialen
dc.typeArticleen
dc.subject.keywords12608000588392carboplatinen
dc.subject.keywordscisplatinen
dc.subject.keywordsgemcitabineen
dc.subject.keywordsglyceryl trinitrateen
dc.subject.keywordslactate dehydrogenaseen
dc.subject.keywordsnavelbineen
dc.subject.keywordspaclitaxelen
dc.subject.keywordsadulten
dc.subject.keywordsadvanced canceren
dc.subject.keywordsageden
dc.subject.keywordsanorexiaen
dc.subject.keywordsarticleen
dc.subject.keywordscancer combination chemotherapyen
dc.subject.keywordscancer radiotherapyen
dc.subject.keywordscancer stagingen
dc.subject.keywordscancer survivalen
dc.subject.keywordscontrolled studyen
dc.subject.keywordsdiarrheaen
dc.subject.keywordsdizzinessen
dc.subject.keywordsdrug effecten
dc.subject.keywordsdrug fatalityen
dc.subject.keywordsfaintnessen
dc.subject.keywordsfemaleen
dc.subject.keywordsfollow upen
dc.subject.keywordsheadacheen
dc.subject.keywordshistopathologyen
dc.subject.keywordshumanen
dc.subject.keywordshypotensionen
dc.subject.keywordsmaleen
dc.subject.keywordsmedication complianceen
dc.subject.keywordsmiddle ageden
dc.subject.keywordsmulticenter studyen
dc.subject.keywordsmultiple cycle treatmenten
dc.subject.keywordsneutrophil counten
dc.subject.keywordsneutrophil lymphocyte ratioen
dc.subject.keywordsnon small cell lung canceren
dc.subject.keywordsobjective tumor responseen
dc.subject.keywordsoncological parametersen
dc.subject.keywordsoutcome assessmenten
dc.subject.keywordsoverall survivalen
dc.subject.keywordspatient complianceen
dc.subject.keywordsphase 3 clinical trialen
dc.subject.keywordspriority journalen
dc.subject.keywordsprogression free survivalen
dc.subject.keywordsrandomized controlled trialen
dc.subject.keywordssurvival rateen
dc.subject.keywordssurvival timeen
dc.subject.keywordsvery elderlyen
dc.relation.urlhttp://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607009042http://dx.doi.org/10.1093/annonc/mdv373en
dc.relation.urlhttp://linksource.ebsco.com/ls.b6e6cc08-c492-42af-aec4-c6084e18e68c.true/linking.aspx?sid=EMBASE&issn=15698041&id=doi:10.1093%2Fannonc%2Fmdv373&atitle=A+phase+III+randomized+trial+of+adding+topical+nitroglycerin+to+first-line+chemotherapy+for+advanced+nonsmall-cell+lung+cancer%3A+The+Australasian+lung+cancer+trials+group+NITRO+trial&stitle=Ann.+Oncol.&title=Annals+of+Oncology&volume=26&issue=11&spage=2280&epage=2286&aulast=Davidson&aufirst=Andrew&auinit=A.&aufull=Davidson+A.&coden=ANONE&isbn=&pages=2280-2286&date=2015&auinit1=A&auinitm=en
dc.identifier.risid679en
dc.description.pages2280-2286en
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Sites:Sunshine Coast HHS Publications
Show simple item record

Page view(s)

108
checked on Apr 17, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.